journal article·2009-05Open access

Neomycin binding preserves extracellular matrix in bioprosthetic heart valves during in vitro cyclic fatigue and storage

Devanathan Raghavan, Barry C. Starcher, Naren R. Vyavahare

Acta Biomaterialia· Volume 5· Issue 4

Abstract

Bioprosthetic heart valve (BHV) cusps have a complex architecture consisting of an anisotropic arrangement of collagen, glycosaminoglycans (GAGs) and elastin. Glutaraldehyde (GLUT) is used as a fixative for all clinical BHV implants; however, it only stabilizes the collagen component of the tissue, and other components such as GAGs and elastin are lost from the tissue during processing, storage or after implantation. We have shown previously that the effectiveness of the chemical crosslinking can be increased by incorporating neomycin trisulfate, a hyaluronidase inhibitor, to prevent the enzyme-mediated GAG degradation. In the present study, we optimized carbodiimide-based GAG-targeted chemistry to incorporate neomycin into BHV cusps prior to conventional GLUT crosslinking. This crosslinking leads to enhanced preservation of GAGs during in vitro cyclic fatigue and storage. The neomycin group showed greater GAG retention after both 10 and 50 million accelerated fatigue cycles and after 1 year of storage in GLUT solution. Thus, additional binding of neomycin to the cusps prior to standard GLUT crosslinking could enhance tissue stability and thus heart valve durability.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Cardiac Valve Diseases and Treatments · Electrospun Nanofibers in Biomedical Applications · Aortic Disease and Treatment Approaches

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (35)

Show source-provided references
1. Prosthetic heart valves: types and echocardiographic evaluation10.1016/j.ijcard.2006.12.037 ↗
2. Reduced calcification of bioprostheses, cross-linked via an improved carbodiimide based method10.1016/j.biomaterials.2003.12.054 ↗
3. Founder’s Award, 25th Annual Meeting of the Society for Biomaterials, perspectives. Providence, RI, April 28–May 2, 1999. Tissue heart valves: current challenges and future research perspectives10.1002/(SICI)1097-4636(19991215)47:4<439::AID-JBM1>3.3.CO;2-F ↗
4. Calcification of tissue heart valve substitutes: progress toward understanding and prevention10.1016/j.athoracsur.2004.06.033 ↗
5. Biological factors affecting long-term results of valvular heterografts10.1016/S0022-5223(19)42561-0 ↗
6. Relevance of immunologic reactions for tissue failure of bioprosthetic heart valves10.1016/0003-4975(95)00291-R ↗
7. Chemically modified collagen: a natural biomaterial for tissue replacement10.1002/jbm.820210606 ↗
8. Degeneration of bioprosthetic heart valve cusp and wall tissues is initiated during tissue preparation: an ultrastructural study
9. Mechanisms of bioprosthetic heart valve failure: fatigue causes collagen denaturation and glycosaminoglycan loss10.1002/(SICI)1097-4636(199907)46:1<44::AID-JBM5>3.0.CO;2-D ↗
10. Stability and function of glycosaminoglycans in porcine bioprosthetic heart valves10.1016/j.biomaterials.2005.08.003 ↗
11. Glycosaminoglycan-targeted fixation for improved bioprosthetic heart valve stabilization10.1016/j.biomaterials.2006.09.005 ↗
12. Glycosaminoglycan-degrading enzymes in porcine aortic heart valves: implications for bioprosthetic heart valve degeneration
13. Extracellular matrix degrading enzymes are active in porcine stentless aortic bioprosthetic heart valves10.1002/jbm.a.10066 ↗
14. Periodate-mediated glycosaminoglycan stabilization in bioprosthetic heart valves10.1002/1097-4636(20010915)56:4<478::AID-JBM1119>3.0.CO;2-C ↗
15. Neomycin prevents enzyme-mediated glycosaminoglycan degradation in bioprosthetic heart valves10.1016/j.biomaterials.2007.02.017 ↗
16. The effect of glycosaminoglycan stabilization on tissue buckling in bioprosthetic heart valves10.1016/j.biomaterials.2007.12.009 ↗
17. Structural requirements for stabilization of vascular elastin by polyphenolic tannins
18. Elastin stabilization in cardiovascular implants: improved resistance to enzymatic degradation by treatment with tannic acid10.1016/j.biomaterials.2003.10.001 ↗
19. Tannic acid treatment enhances biostability and reduces calcification of glutaraldehyde fixed aortic wall10.1016/j.biomaterials.2004.04.034 ↗
20. Determination of the elastin content of tissues by measuring desmosine and isodesmosine10.1016/0003-2697(77)90372-4 ↗
21. A colorimetric method for the determination of glucosamine and chondrosamine10.1042/bj0271824 ↗
22. Prevention of calcification in bioprosthetic heart valves: challenges and perspectives10.1517/14712598.4.12.1971 ↗
23. Biomechanics of engineered heart valve tissues10.1109/IEMBS.2006.259756 ↗
24. Stress variations in the human aortic root and valve: the role of anatomic asymmetry10.1114/1.122 ↗
25. Prosthetic heart valves: catering for the few10.1016/j.biomaterials.2007.09.033 ↗
26. Bioprosthetic heart valves: the need for a quantum leap10.1042/BA20030211 ↗
27. Mechanics of cryopreserved aortic and pulmonary homografts
28. Hyaluronidase and its substrate hyaluronan: biochemistry, biological activities and therapeutic uses10.1016/S0304-3835(98)00195-5 ↗
29. Biodegradation of hyaluronic acid derivatives by hyaluronidase10.1016/0142-9612(94)90248-8 ↗
30. Padera · 2003
31. Aortic valve cusp microstructure: the role of elastin10.1016/0003-4975(95)00263-K ↗
32. The role of elastin in aortic valve mechanics10.1016/S0021-9290(97)00122-X ↗
33. The effect of elastin damage on the mechanics of the aortic valve10.1016/S0021-9290(00)00187-1 ↗
34. Update of the European standards for inactive surgical implants in the area of heart valve prostheses10.1016/j.ejcts.2007.08.015 ↗
35. The evolution of bioprosthetic heart valve design and its impact on durability10.1016/S1054-8807(03)00075-9 ↗